Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
paid
expect many approvals through out europe can see this flying above 10p
Eden Research Plc
("Eden" or "Company")
Eden obtains authorisation for Mevalone in Poland
Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that its flagship biofungicide, Mevalone®, has received regulatory authorisation in Poland. The certification will allow farmers to apply Mevalone to their wine and table grapes to protect and treat outbreaks of Botrytis cinerea as well as on apples to prevent post-harvest storage diseases thereby helping to reduce food waste in the supply chain.
SumiAgro Europe has been appointed as the Company's exclusive distributor of Mevalone in the territory with product distribution expected to commence imminently. SumiAgro has extensive experience with Mevalone, having previously supported Eden with significant label extensions in France.
Poland represents a significant new market for Eden and the commercialisation of Mevalone, given it is the EU's largest producer of apples, producing almost 2.5 million tons annually. Eden expects to receive additional regulatory approvals in due course in additional Central European member states such as Germany, Austria, and Hungary, where high levels of wine production are found. Central Europe is a strategic target market for Eden with the ultimate addressable market for Eden's products being comparable in value to that of Southern Europe and potential sales of Mevalone estimated to peak at €3.2m.
now
moving up
on the leaderboard now
up 6 percent this morning
rns out
GOOD START THIS MORNING
https://m.youtube.com/watch?v=-gnq2zCnLJ0&list=PLsZDu0mZ9Vf-f6WCrQG9S_hlb2CB1BmOB&index=3
Tomatoes, peppers etc etc.
Sipcam Iberia recently brought attention to one of the huge areas being sprayed with ARAW.
https://t.co/qd3cK6c6Ip
Looks like another fund raise this year...
https://www.youtube.com/watch?v=SqGg7SxwV8I
Also bear in mind from Interim results this statement:
Our cash generation is supported by the material progress made along various development lines, as well as the growing number of additional commercial agreements and regulatory approvals in new territories.
We continue to aggressively manage our cash position and always aim to achieve operational efficiencies. Much of the work that has been brought in-house was previously contracted to third parties, and so many of our internal costs have offset what were previously larger third-party expenditures. By bringing certain strategic capabilities in-house, we have also been able to significantly reduce development time whilst building internal know-how and strengthening our strategic capabilities in support of future growth.
Corteva have a very interesting history:
"Corteva Agriscience™ is founded on the rich heritages of Dow, DuPont and Pioneer. Discover our history and evolution."
https://www.corteva.com/who-we-are/our-history.html
Today' s one sez, expressed in simpul ingrish:
BGF Investment Management Ltd (if you need chaper & worse, account BGF Investments LP at/with the nominal shareholder, Pershing Securities Ltd acting via Pershing Nominees Ltd, of Liverpool)....
.... used to hold about 57,000,000 shares in Eden Research plc, i.e. about 14.962% of the voting rights, but
.... on or just before September 30, 2022 it flogged off about 3,750,000 shares , reducing its holding to about 53,250,000 shares (13.977%).
I strongly suspect more are to come.
;D
This type of obsessive behaviour is invariably the output of ex employees who have been dismissed for misconduct (dishonesty, fraud, sexual harassment etc).
These paid-for advertisements in promotion websites would be even funnier if so many suckers didn't fall for the BS.
The marketplace is saturated with competent and sales-oriented biotechs.
This one isn't worth the candle.
Is this your view of all managements where the stock price is down, or just Eden? Do you own shares in the company?
What is the reason for all the hate directed at the company and the management?
What a fiasco... offloading soon apace.
A way needs to be found to clawback all the salaries etc paid to these overpaid cvnts and their cronies....
Long awaited good news on US regulatory approval - only took 4 years! But individual State approval still needed apparently and no beginning in sight of those "meaningful" sales. The trouble is that EU sales have been fairly non-existent. And Director salaries are simply exorbitant (yes please). I will watch and wait.
Halve the salaries as a minimum and replace with stock. Stock falls, so does their salary. Might prompt them to leave